SIDP has developed guidance documents pertaining to the use of remdesivir (Veklury®) for the treatment of COVID-19 for both outpatient and inpatient administration of 3 and 5 day regimens, informed by the experiences of pharmacists who have implemented remdesivir therapeutic regimens at their medical centers.
SIDP member, Drew Zimmer, PharmD (left), discussing therapeutic options for COVID-19 with a colleague.
How to use this Toolkit
1. Review toolkit contents.
2. Download documents and customize (if needed) to fit your institutional needs.
3. Review educational materials and customize (if needed) to fit your institutional needs.
Updates and revisions to toolkit contents will be made every 2 weeks, as needed, until May 2024.
Revisit this page periodically for the most up-to-date information!
Please keep in mind that information, data regarding COVID-19 therapeutics is constantly evolving. Use of SIDP guidelines and/or toolkits are intended as recommendations. Use does not supersede clinical judgement based on the assessment of an individual patient by an individual practitioner. The recommendations reflect the best available evidence at the time of publication and are not the sole resource for patient care management and/or an exclusive source of action.
SIDP COVID-19 Remdesivir Toolkit Taskforce Members
Special thanks to the following SIDP members for volunteering their time and efforts to the development of this toolkit:
SIDP Member, Christina O'Connor, PharmD (left) discussing therapeutic options for COVID-19 with an advanced practice practitioner colleague.
This toolkit was supported in part by Gilead Sciences, Inc. All content creation and peer review were conducted independently by SIDP members.
Release Date 5/10/2023, Updated 8/11/2023